Rana R. McKay, MD

Rana R. McKay, MD, FASCO, highlights notable takeaways from the COMRADE trial, assessing the combination of olaparib plus radium-223 in CRPC.

Rana R. McKay, MD, FASCO, outlines findings from a study looking at the somatic, germline, and immunologic landscapes of UTUC and UCB tumors.

Rana R. McKay, MD, FASCO, details the key efficacy and safety findings from the phase 2 COMRADE trial.

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.

"Radium-223 continues to have a very significant role for patients with advanced castration-resistant prostate cancer," says Rana R. McKay, MD, FASCO.

"Our findings highlight that completing 5 cycles or more of radium was associated with a 2- to 5-fold increase in overall survival," says Rana R. McKay, MD, FASCO.

Many factors play into decision-making process when weighing agents.

Patients with cancer are particularly susceptible to negative consequences of COVID-19.